Flow Cytometry: CD34 Antibody (ICO-115) [NBP2-29455] - Analysis using the PE conjugate of NBP2-29455. Surface Staining of CD34 on KG-1 cells using CD34 antibody (red) and isotype control (green) at 5 ul/0.5 ug/10^6 ...read more
Flow Cytometry: CD34 Antibody (ICO-115) [NBP2-29455] - Surface flow cytometric analysis of CD34 on KG-1 cells using CD34 antibody (red) and isotype control (green) at 0.5 ug/10^6 cells.
Blast cells from a chronic myeloid leukemia patient were used as the immunogen for the CD34 antibody.
Hematopoietic Stem Cell Marker
This antibody recognizes a single chain, transmembrane, heavily glycosylated protein of 90-120kDa, which is identified as CD34. Its expression is a hallmark for identifying pluripotent hematopoietic stem or progenitor cells. Its expression is gradually lost as lineage committed progenitors differentiate. CD34 is a marker of choice for staining blasts in acute myeloid leukemia. In addition, it is expressed by soft tissue tumors, such as solitary fibrous tumor and gastrointestinal stromal tumor. CD34 expression is also found in vascular endothelium. Additionally, it appears that proliferating endothelial cells overexpress this molecule than the non-proliferating endothelial cells. Anti-CD34 labels > 85% of angiosarcoma and Kaposi's sarcoma, but shows low specificity.
Protein A or G purified
Test in a species/application not listed above to receive a full credit towards a future purchase.
CD34 a type 1 transmembrane protein, belonging to the sialomucin family, has important roles in adhesion which remain to be fully elucidated. CD34 has an intracellular cytoplasmic domain containing consensus sites for serine, theronine, tryrosine and active protein kinase C (PKC) phosphorylation thereby implicating a role for the protein in signal transduction processes. CD34 expression, as identified by antibody, is a hallmark for identifying pluripotential hematopoietic stem or progenitor cells. CD34 antibody positive populations expand and differentiate into the various lymphohematopoietic lineages. During differentiation, lineages lose CD34 expression and become CD34 antibody negative.
CD34 is also expressed on vascular endothelium, bone marrow stroma, embryonic fibroblasts, and neurons and antibody to CD34 is also useful in analyzing these populations. Positive staining has also been described in a number of malignancies including various sarcomas and fibromas, preB-ALL, peripheral nerve sheath tumors, and papillary thyroid carcinoma. If certain kinds of tumors are characteristically positive for CD34 antibody staining such as Ewing's sarcoma, a CD34 antibody negative result may potentially rule out that particular tumor.
This product is for research use only and is not approved for use in humans or in clinical diagnosis. Primary Antibodies are guaranteed for 1 year from date of receipt.
Tissue Processing:The brain tissue was embedded in OCT and put in a glass beaker containing isopentane. The beaker was quickly placed in liquid nitrogen and the tissue was frozen. Removed tissue into -80 ° C for storage; Remove out the tissue from -80 ° C and equilibrate in the freezing microtome for one hour.
Product General Protocols
Find general support by application which include: protocols, troubleshooting, illustrated assays, videos and webinars.
FAQs for CD34 Antibody (NBP2-29455). (Showing 1 - 1 of 1 FAQs).
I wonder if you have a CD105 or CD34 antibody suitable for IHC that is specific for human and do not bind mouse?
We do not have any anti-human CD34 or CD105 antibodies that are confirmed to NOT detect the mouse protein. When we have tested an antibody and confirmed that it will not react with mouse samples, we will add Mu(-) to the datasheet, and unfortunately all of our CD105 and CD34 antibodies will either detect the mouse protein, or they have not been used in mouse samples before.
The concentration calculator allows you to quickly calculate the volume, mass or concentration of your vial. Simply enter your mass, volume, or concentration values for your reagent and the calculator will determine the rest.
PRODUCT AVAILABILITY: Update Regarding the Evolving COVID-19 Situation
Bio-Techne appreciates the critical role that you and our products and services play in research efforts to further scientific innovation and discovery. We are continually assessing our manufacturing and supplier capabilities during the COVID-19 situation and are implementing precautionary measures to ensure uninterrupted supply of products and services. Currently, and as we abide by local shelter in place orders across the world, we are fully operational and do not anticipate any material supply disruptions across our Bio-Techne brands and product lines. As the situation evolves, our goal is to utilize preventive measures to reduce the threat that COVID-19 poses to our ability to meet the needs of our customers globally.